Form 4: Corcept Therapeutics CEO Joseph Belanoff Sells Shares Under 10b5-1 Trading Plan

Corcept Therapeutics CEO Joseph Belanoff sold 1,974 shares of common stock at an average price of $60.8329 per share on March 24, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 24, 2025, Joseph K. Belanoff, CEO of Corcept Therapeutics, sold 1,974 shares of common stock.
• The sale was executed at a weighted average price of $60.8329 per share, with individual sale prices ranging from $60.83 to $60.93.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on November 26, 2024.
• Following the transaction, Belanoff directly owns 3,017,437 shares.
• Belanoff also has indirect ownership through the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust DTD 04/29/02, over which he has voting power but disclaims beneficial ownership except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a stock sale under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.

Industry Context

Sales by insiders are a common occurrence, and the use of 10b5-1 trading plans allows insiders to sell shares over a period of time without being accused of trading on inside information. It is important to monitor insider sales in conjunction with other news and financial data to assess the overall health and prospects of the company.

Comparison to Industry Standards

• Insider trading activity is closely monitored across the pharmaceutical industry.
• Companies like Pfizer, Johnson & Johnson, and Merck are often compared to Corcept Therapeutics in terms of market capitalization and drug development pipelines.
• Analyzing insider sales as a percentage of total shares outstanding can provide a benchmark against industry peers.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders if it creates downward pressure on the stock price, although the effect is likely to be minimal given the relatively small number of shares sold compared to the total outstanding shares.
• The sale does not appear to have any direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, Corcept Therapeutics, CORT, Joseph Belanoff, CEO, Stock Sale, 10b5-1 Trading Plan, Beneficial Ownership